Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of CP 690,550 in Patients With Active Rheumatoid Arthritis on Background Methotrexate

Trial Profile

Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of CP 690,550 in Patients With Active Rheumatoid Arthritis on Background Methotrexate

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary) ; Adalimumab
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ORAL-Standard
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Nov 2023 Results of a mediation modeling analysis presented at the ACR Convergence 2023
    • 05 Apr 2022 Results of post-hoc pooled analysis (ORAL Scan; ORAL Standard; ORAL Sync) assessing impact of tofacitinib on fatigue, sleep, and HRQoL and explored associations between fatigue, related patient-reported outcomes (PROs), and disease activity in RA patients, published in the Arthritis Research and Therapy.
    • 01 Mar 2022 Results evaluating the impact of tofacitinib using posthoc analysis of phase III and phase IIIb/IV trials published in The Journal of Rheumatology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top